Allo-aca (TFA)

• Description :

  Allo-aca TFA, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca TFA blocks leptin signaling and action in numerous in vitro and in vivo models[1][2].

• UNSPSC :

  12352209

• Target :

  Neuropeptide Y Receptor

• Type :

  Peptides

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/allo-aca-tfa.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(NC1=CC(OC(C=C2CC(N)=O)=O)=C2C=C1)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@@H](O)C)N.OC(C(F)(F)F)=O

• Molecular Formula :

  C50H76F3N13O17

• Molecular Weight :

  1188.21

• References & Citations :

  [1]Otvos L Jr, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011;47 (10) :1578-1584.|[2]Coroniti R, et al. Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models [published correction appears in Front Mol Biosci. 2016 Nov 18;3:75]. Front Mol Biosci. 2016;3:67. Published 2016 Oct 13.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported